Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Home

Get in touch

Menu

Prescribing Information

TZIELD (teplizumab) can give patients more symptom-free time in Stage 2 autoimmune T1D vs placebo, delaying a lifetime of symptom management and insulin therapy1–3

A delay in the onset of stage 3 T1D may provide your patients with:

More insulin-free years4-6

Delaying the social stigma and lifestyle disruptions that come with managing T1D4,5,7

Time for vigilant monitoring of signs and symptoms of DKA6

To reduce the risk of hospitalisation with DKA6

Increased opportunities to learn about glycaemic control8

So your patients can learn how to properly manage their disease9

Get in Touch with Us

Questions? Leave your details and we'll reach out to you at your preferred time.

Get in touch

INDICATION: TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years of age and older with Stage 2 T1D.4

T1D, Type 1 diabetes.

  1. Sims EK, et al. Sci Transl Med. 2021; 13(583): eabc8980.
  2. Insel RA, et al. Diabetes Care. 2015; 38(10): 1964–1974.
  3. Lledó-Delgado A, et al. J Clin Invest. 2024; 134(18): e177492.
  4. TZIELD® (teplizumab) UK Summary of Product Characteristics.
  5. Edelman S. J Fam Pract. 2023; 72(6 Suppl): S19-S24.
  6. Ayers AT, et al. J Diabetes Sci Technol. 2025; 19(6): 1441-1447.
  7. Ashraf MN and Cheng AYY. Diabetes Ther. 2024; 15(2): 311-316.
  8. Phillip M, et al. Diabetes Care. 2024; 47(8): 1276-1298.
  9. American Diabetes Association Professional Practice Committee. Diabetes Care. 2022; 45(Suppl 1): S83-S96.

MAT-XU-2500772 (v2.0) | June 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: +44 (0) 800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com
Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
Staying in TouchTerms of UseCookie PolicySitemapAccessibility Statement

© Sanofi 2026. All rights reserved.

MAT-XU-2300297 (v8.0) - Date of Preparation: December 2025

Privacy Notice Update | We have updated our Privacy Notice for Healthcare Professionals to improve your experience collaborating with us, maintain high standards of privacy and ultimately strengthen the trust you place in us. Key improvements include enhanced clarity on why and how Sanofi processes your personal data.
Staying in TouchTerms of UseCookie PolicySitemapAccessibility Statement

© Sanofi 2026. All rights reserved.

MAT-XU-2300297 (v8.0) - Date of Preparation: December 2025